We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determinants of Compliance With Glaucoma Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00362622
First Posted: August 10, 2006
Last Update Posted: August 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Alcon Research
Information provided by (Responsible Party):
Christopher Girkin, MD, University of Alabama at Birmingham
  Purpose
To determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the Travalert device.

Condition
Open Angle Glaucoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determinants of Compliance With Glaucoma Therapy

Resource links provided by NLM:


Further study details as provided by Christopher Girkin, MD, University of Alabama at Birmingham:

Enrollment: 59
Study Start Date: October 2005
Study Completion Date: January 2008
Detailed Description:
To determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the Travalert device. All participants will have open angle glaucoma.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Glaucoma patients.
Criteria

To be eligible to participate in the study, patients had to be (1) 19 years or older; (2) have a diagnosis of open angle glaucoma (OAG) in 1 or both eyes or ocular hypertension; and (3) using a prostaglandin ocular hypotensive medication in 1 or both eyes.

The protocol excluded patients with uncontrolled IOP control, known contraindications to Travoprost, clinically significant systemic disease that would interfere with the study, participation in any other research study within 30 days, or change in systemic medications that may alter IOP within 30 days before recruitment.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00362622


Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Alcon Research
Investigators
Principal Investigator: Christopher A Girkin, MD University of Alabama at Birmingham
Principal Investigator: Jason Swanner, MD University of Alabama at Birmingham
Principal Investigator: Matthew Sapp, MD University of Alabama at Birmingham
  More Information

Responsible Party: Christopher Girkin, MD, Chairman/Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00362622     History of Changes
Other Study ID Numbers: X050826003
First Submitted: August 9, 2006
First Posted: August 10, 2006
Last Update Posted: August 16, 2012
Last Verified: August 2012

Keywords provided by Christopher Girkin, MD, University of Alabama at Birmingham:
Travalert
open angle glaucoma

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases